Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Total Assets of $1.39 billion for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +21.5% in Total Assets from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $12.35 million | Q2 2011: $13.29 million | Q4 2011: $23.06 million | Q1 2012: $20.08 million | Q2 2012: $16.49 million | Q4 2012: $15.23 million | Q1 2013: $12.42 million | Q2 2013: $41.49 million | Q4 2013: $92.69 million | Q1 2014: $202.64 million | Q2 2014: $196.62 million | Q4 2014: $162.14 million | Q1 2015: $162.38 million | Q2 2015: $145.19 million | Q4 2015: $111.38 million | Q1 2016: $94.61 million | Q2 2016: $85.53 million | Q4 2016: $144.26 million | Q1 2017: $126.87 million | Q2 2017: $115.08 million | Q4 2017: $88.22 million | Q1 2018: $127.00 million | Q2 2018: $112.90 million | Q4 2018: $340.95 million | Q1 2019: $333.94 million | Q2 2019: $336.83 million | Q4 2019: $587.60 million | Q1 2020: $561.08 million | Q2 2020: $555.73 million | Q4 2020: $499.25 million | Q1 2021: $756.80 million | Q2 2021: $734.93 million | Q4 2021: $638.54 million | Q1 2022: $703.58 million | Q2 2022: $751.78 million | Q4 2022: $891.49 million | Q1 2023: $891.31 million | Q2 2023: $795.86 million | Q4 2023: $626.29 million | Q1 2024: $955.15 million | Q2 2024: $883.76 million | Q4 2024: $1.01 billion | Q1 2025: $1.57 billion | Q2 2025: $1.38 billion | Q3 2025: $1.39 billion | Q4 2025: $1.60 billion.
- Over the full 15 years of available data (2011 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Total Assets has grown by 8,618.8%.
- Historical annual values: Fiscal year 2025: $1.39 billion | Fiscal year 2024: $1.14 billion | Fiscal year 2023: $765.55 million | Fiscal year 2022: $691.94 million | Fiscal year 2021: $710.15 million | Fiscal year 2020: $522.50 million | Fiscal year 2019: $349.85 million | Fiscal year 2018: $111.61 million | Fiscal year 2017: $104.02 million | Fiscal year 2016: $128.18 million | Fiscal year 2015: $132.27 million | Fiscal year 2014: $182.82 million | Fiscal year 2013: $37.33 million | Fiscal year 2012: $16.53 million | Fiscal year 2011: $15.89 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: